| __timestamp | Blueprint Medicines Corporation | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 7751000 |
| Thursday, January 1, 2015 | 14456000 | 10251000 |
| Friday, January 1, 2016 | 19218000 | 9575000 |
| Sunday, January 1, 2017 | 27986000 | 10912000 |
| Monday, January 1, 2018 | 47928000 | 11049000 |
| Tuesday, January 1, 2019 | 96388000 | 11646000 |
| Wednesday, January 1, 2020 | 157743000 | 13265000 |
| Friday, January 1, 2021 | 195293000 | 25805000 |
| Saturday, January 1, 2022 | 237374000 | 35182000 |
| Sunday, January 1, 2023 | 295141000 | 94999000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing insights
In the competitive landscape of biotechnology, effective cost management is crucial. Blueprint Medicines Corporation and Viridian Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Blueprint Medicines saw a staggering 3,640% increase in Selling, General, and Administrative (SG&A) expenses, peaking at nearly $295 million in 2023. This reflects their aggressive expansion and investment in growth.
Conversely, Viridian Therapeutics, while also experiencing growth, maintained a more conservative trajectory, with SG&A expenses increasing by approximately 1,125% to $95 million in the same period. This strategic restraint may indicate a focus on sustainable scaling.
Understanding these trends provides valuable insights into how these companies navigate financial challenges and opportunities in the biotech sector, offering lessons in balancing growth with fiscal responsibility.
Selling, General, and Administrative Costs: Merck & Co., Inc. vs Blueprint Medicines Corporation
Amgen Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Opthea Limited
Blueprint Medicines Corporation or CymaBay Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Iovance Biotherapeutics, Inc.
Blueprint Medicines Corporation or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Iovance Biotherapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Taro Pharmaceutical Industries Ltd. or Viridian Therapeutics, Inc.
Celldex Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Evotec SE and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared